# Neoadjuvant Chemotherapy and Tilelizumab in Stage III（cTNM-IIIA.IIIB）Non-small-cell Lung Cancer

> **NCT04865705** · PHASE2 · UNKNOWN · sponsor: **West China Hospital** · enrollment: 33 (estimated)

## Conditions studied

- Stage III
- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** tislelizumab

## Key facts

- **NCT ID:** NCT04865705
- **Lead sponsor:** West China Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-11-10
- **Primary completion:** 2021-12-10
- **Final completion:** 2022-06-10
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2021-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04865705

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04865705, "Neoadjuvant Chemotherapy and Tilelizumab in Stage III（cTNM-IIIA.IIIB）Non-small-cell Lung Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04865705. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*